Clinical trials: Normal Skin
Respiratory, Lung
Feasibility of AI-based Classification of Normal, Wheeze and Crackle Sounds From Stethoscope in Clinical Settings
Assessing the feasibility and testing the accuracy of the developed artificial intelligence algorithms for detection of wheezes and crackles in patients with lung pathologies in clinical settings on unseen local patient data…
- Trial name
- NCT05268263
- Testing
- Artificial Intelligence Algorithm
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Innova Smart Technologies (Pvt.) Ltd
Breast Cancer
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality.
- Trial name
- SGLT2i/DPPi (NCT07436663)
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Melanoma
Post-Approval Study of MelaFind
The purpose of this study is to collect data to describe the real-world use and safety and effectiveness of MelaFind® in a post-approval clinical setting.
- Trial name
- NCT01700114
- Testing
- MelaFind
- Where
- 6 sites in United States
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism
The LUVIA study is a randomized placebo-controlled trial designed to investigate the effects of lutein and zeaxanthin supplementation on macular pigment and visual function in ocular or oculocutaneous albinism.
- Trial name
- LUVIA (NCT02200263)
- Testing
- Lutein plus Zeaxanthin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Lupus Nephritis
The Expression Profile of New Complement Components in Childhood Lupus Nephritis
The aim of this study was to evaluate whether C4d is a better biomarker and examine whether C4d plasma levels correlate with treatment response and C4d kidney deposition in systemic lupus erythematosus (SLE) with lupus nephritis…
- Trial name
- NCT05082363
- Testing
- C4d evaluation in lupus nephritis in serum and renal tissue
- Volunteers
- 30 people
- Sponsor
- Assiut University
Atopic Dermatitis
Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis
The aims of this study are: 1. Compare the efficacy of Lindioil ointment and Protopic® ointment in treating atopic dermatitis. 2. Compare the safety of Lindioil ointment and Protopic® ointment in treating atopic dermatitis. 3.
- Trial name
- NCT03614221
- Testing
- Lindioil ointment, Protopic ointment 0.1%
- Where
- 2 sites in Taiwan
- Volunteers
- 22 people
- Sponsor
- Chang Gung Memorial Hospital
MPS IIIA, Sanfilippo Syndrome
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.
- Conditions
- MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
- Trial name
- NCT02716246
- Testing
- UX111, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 36 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Breast Neoplasms, Metastases, Neoplasm
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
Paclitaxel (Taxol, Bristol-Meyers Squibb) has been shown to be very effective against metastatic breast cancer, as well as other cancers.
- Trial name
- NCT00046527
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Celgene Corporation
Acne Vulgaris
Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).
- Trial name
- NCT02411942
- Testing
- Adapalene Gel 0.3%, Differin®
- Volunteers
- 753 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Comparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris
There is no local data available regarding the comparative efficacy of topical clascoterone and topical adapalene, particularly in patients with mild acne vulgaris.
- Trial name
- NCT07673094
- Testing
- Clascoterone Cream 1%, Adapalene 0,1% cgel
- Volunteers
- 60 people
- Sponsor
- Khyber Teaching Hospital
Atopic Dermatitis
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18 years of age) or severe AD…
- Trial name
- NCT02407756
- Testing
- Dupilumab
- Where
- 26 sites in Canada, Czechia and 4 more
- Volunteers
- 78 people
- Sponsor
- Regeneron Pharmaceuticals
Pressure Ulcer, Skin Lesion
Prevention of Skin Damage in the Patient in Prone Position: Development of Education Interventions Based on a Training Needs Assessment Study.
This is study 1 of 3 - of the overall project: The ProneTection Quality Improvement Project. The three aims of this study, study 1 are: 1.
- Conditions
- Pressure Ulcer, Skin Lesion, Acute Respiratory Distress Syndrome
- Trial name
- NCT05238870
- Testing
- Interviews for the needs analysis. No intervention.
- Where
- 2 sites in Belgium
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Ghent
Acne Vulgaris
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
- Trial name
- NCT04321070
- Testing
- Clindamycin Phosphate, Clindamycin Phosphate RLD
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related…
- Trial name
- NCT03769168
- Testing
- Secukinumab
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Eczema
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema.
- Trial name
- NCT06807268
- Testing
- Abrocitinib
- Where
- 47 sites in United States, China and 6 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis (JIA), Childhood Rheumatic Diseases
Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients
Juvenile idiopathic arthritis (JIA) is the primary rheumatic disease reported to affect the pediatric population. Research suggests that parents' thoughts and feelings about their child's pain, specifically with JIA diagnosis…
- Trial name
- NCT07185750
- Testing
- Questionnaire application for JIA cases and their parents
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hacettepe University
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00003418
- Testing
- exemestane, tamoxifen citrate
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 4,400 people
- Sponsor
- International Collaborative Cancer Group
Morquio Syndrome A, Maroteaux Lamy Syndrome
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
The purpose of this study is to identify patients with Morquio syndrome type A (MPS IVA) and Maroteaux-Lamy syndrome (MPS VI) who may have been missed or misdiagnosed due to atypical clinical features, a milder course, and/or…
- Conditions
- Morquio Syndrome A, Maroteaux Lamy Syndrome, MPS IVA, MPS VI
- Trial name
- NCT01961518
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Greenwood Genetic Center
Hereditary Angioedema (HAE)
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
The main aim of this study is to compare the number of HAE attacks occuring in persons using lanadelumab with the number of HAE attacks before lanadelumab treatment was started.
- Trial name
- ENABLE (NCT04130191)
- Where
- 19 sites in Austria, Germany and 5 more
- Volunteers
- 140 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.